公开(公告)号：KR100750287B1

公开(公告)日：2007-08-20

申请号：KR1020060100430

申请日：2006-10-16

Applicant: 한국화학연구원

Inventor： 김문석 ,  이해방 ,  송인범 ,  조미희 ,  현훈 ,  김유한 ,  이정원 ,  강길선

IPC: A61L27/36 ,  A61L27/52 ,  A61K35/38 ,  A61F2/04

公开(公告)号：KR100832552B1

公开(公告)日：2008-05-26

申请号：KR1020060125541

申请日：2006-12-11

Applicant: 한국화학연구원

Inventor： 김문석 ,  이해방 ,  현훈 ,  김유한 ,  이정원 ,  송인범 ,  조미희 ,  강길선

IPC: A61K9/08 ,  A61K31/765

CPC classification number: A61K47/34 ,  A61K9/0019 ,  A61K9/06 ,  A61K38/28 ,  A61K38/38

Abstract: An injection formulation of a drug is provided to release a desired amount of the drug gradually for a desired time to a portion desired by a drug person administered to the drug by using a bio-compatible and thermosensitive polyethyleneglycol/polyester block copolymer to make the drug semi-solid or gel. An injection formulation comprises a hydrophilic portion consisting of polyethyleneglycol having a molecular weight of 350-2,000g/mole and a biodegradable polyester hydrophobic portion containing a caprolactone(CL) segment as an essential ingredient and at least one of a paradioxanone(PDO) segment and a trimethylene carbonate(TMC) segment and is characterized in that it is prepared by mixing a protein or peptide-based drug with a bio-compatible and thermosensitive polyethyleneglycol/biodegradable polyester block copolymer having a molecular weight of 2,000-7,000g/mole, wherein the protein or peptide-based drug is albumin, calcitonin, octreotide, leuprolide, adenosine deaminase, L-asparaginase, urokinase, interferon alpha-2b, interferon beta-1b, human insulin, insulin-like growth factor-1(IGF-1), erythropoietin(EPO), granulocyte colony stimulating factor(G-CSF), human growth hormone(hGH), nerve growth factor(NGF), brain-derived neurotrophic factor(BDNF), neurotrophin-3(NT-3), fibroblast growth factor(FGF), epidermal growth factor(EGF), endothelial growth factor(VEGF), transforming growth factor-beta(TGF-beta) or platelet-derived growth factor(PDGF).

Abstract translation: 提供药物的注射制剂，通过使用生物相容性和热敏性聚乙二醇/聚酯嵌段共聚物将所需量的药物逐渐释放到药物给药的人所需的部分，以制备药物 半固体或凝胶。 注射制剂包含由分子量为350-2,000g / mol的聚乙二醇组成的亲水部分和含有己内酯（CL）链段作为必需成分的可生物降解的聚酯疏水部分和至少一种对二恶烷酮（PDO）链段和 一种三亚甲基碳酸酯（TMC）片段，其特征在于其通过将蛋白质或肽基药物与分子量为2,000-7,000g / mol的生物相容性和热敏聚乙二醇/可生物降解的聚酯嵌段共聚物混合而制备，其中 蛋白质或肽类药物是白蛋白，降钙素，奥曲肽，亮丙瑞林，腺苷脱氨酶，L-天冬酰胺酶，尿激酶，干扰素α-2b，干扰素β-1b，人胰岛素，胰岛素样生长因子-1（IGF-1） ，红细胞生成素（EPO），粒细胞集落刺激因子（G-CSF），人生长激素（hGH），神经生长因子（NGF），脑源性神经营养因子（BDNF），神经营养因子-3（NT-3），成纤维细胞 生长因子（FGF），表皮生长因子（EGF），内皮生长因子（VEGF），转化生长因子-β（TGF-β）或血小板衍生生长因子（PDGF）。